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Background and purpose: Tumor motion plays a key role in the safe delivery of
Stereotactic Body Radiotherapy (SBRT) for pancreatic cancer. The purpose of this study
was to use tumor motion data measured in patients to establish limits on motion magnitude
for safe delivery of pancreatic SBRT, and to help guide motion-management decisions in
potential dose-escalation scenarios.
Materials and methods: Using 91 sets of pancreatic tumor motion data measured
in patients, we calculated motion-convolved dose of the gross tumor volume (GTV), the
duodenum and the stomach for 25 pancreatic cancer patients. We derived simple linear or
quadratic models relating motion to changes in dose, and used these models to establish the
maximum amount of motion allowable while satisfying error thresholds on key dose metrics.
In the same way, we studied the effects of dose escalation and tumor volume on allowable
motion.
Results: In our patient cohort, the mean [minimum—maximum] allowable motion for
33/40/50 Gy to the PTV was 11.9 [6.3—22.4], 10.4 [5.2—19.1] and 9.0 [4.2—16.0] mm,
respectively. Maximum allowable motion decreased as dose was escalated, and was smaller
in patients with larger tumors. We found significant differences in allowable motion between
different plans, suggesting a patient-specific approach to motion management is possible.
Conclusion: The effects of motion on pancreatic SBRT are highly variable between patients
and there is potential to allow more motion in certain patients, even in dose-escalated
scenarios. In our dataset, a conservative limit of 6.3 mm would ensure safe treatment of all
patients treated to 33 Gy in 5 fractions.
This manuscript was submitted to Practical Radiation Oncology
INTRODUCTION
At the time of diagnosis, approximately 50% of pan-
creatic cancer patients present with distant metastases
and 30% of the patients have locally advanced disease
[1]. Surgery is the preferred therapeutic option, but can-
not be used in patients with either locally advanced or
borderline resectable disease due to vascular involvement.
Radiation plays a role in this setting, with the goal of ei-
ther converting patients to surgical candidates or achiev-
ing local control of the tumor. Stereotactic Body Radia-
tion Therapy (SBRT) has demonstrated promising early
results [2, 3, 4]. However, the proximity of the pancreas
to the radiosensitive organs of the abdomen (such as the
small bowel, stomach, kidneys, and spinal cord) makes
curative radiotherapy difficult.
SBRT delivers large, ablative doses of radiation in only
a few treatment fractions. SBRT can maximally spare
the surrounding normal tissues by forming sharp dose
gradients around the treatment volume [5, 6]. In re-
cent years, multiple clinical trials have shown encourag-
ing clinical outcomes of pancreatic cancer patients after
SBRT [2, 7, 8, 3, 4, 9]. Furthermore, SBRT can po-
tentially improve distant control by inducing immune re-
sponse [10, 11, 12]. Current evidence suggests that dose
escalation in SBRT may further improve patient out-
comes [13, 14, 15, 16, 17], and many institutional trials
of dose-escalated pancreatic SBRT are under way [18].
However, dose escalation is limited by toxicities to the
surrounding organs at risk (OARs). OARs in pancreatic
SBRT include stomach and duodenum [19], because they
are highly sensitive to radiation and adjacent to the pan-
creas. The location of tumor, duodenum and stomach
in one patient are shown in Figure 1. Due to breath-
ing, digestion, and heartbeat, the boundary between the
tumor and nearby OARs is blurred. This internal target
movement may lead to underdosage in parts of the tumor
and overdosage to the OARs. As dose to the tumor esca-
lates, these dose differences will grow larger, potentially
increasing toxicity and decreasing local control.
To mitigate the detrimental effects on treatment due to
the internal organ motion, techniques such as abdominal
compression, respiratory gating, breath-hold, and real-
time tumor tracking [20] can be applied. Each technique
provides different tradeoffs between ease of use, patient
comfort, and the magnitude of motion reduction. The
AAPM task group 76 has advised an individual approach
to respiratory management [20]; however, there is little
clinical guidance on how to achieve this patient-specific
management for pancreatic cancer patients. In this pa-
2Fig. 1 The location of pancreatic tumor (GTV, red), duodenum
(purple) and stomach (green) for a patient on a 3D CT scan.
per, we use tumor motion data measured in patients to
a) quantify the effects of pancreatic motion on clinical
dose distributions, and b) calculate the allowable tumor
motion for individual patients. The purpose of our work
is to develop a method for determining patient-specific
motion limits. We utilize this method to answer three
key clinical questions: How much motion is allowable
during treatment while still achieving clinical dose con-
straints? Does allowable motion change accordingly in
larger tumors or with dose escalation? Finally, is there a
way to identify treatment plans that are more tolerant to
motion, potentially allowing these patients to be treated
with less onerous motion mitigation techniques?
METHODS AND MATERIALS
Patients
Between November 2015 and July 2017, we treated 25
newly diagnosed pancreatic adenocarcinoma cases with
Volumetric Modulated Arc Therapy (VMAT) to a dose
of 33 Gy in five fractions using 6—10 MV photons. More
details regarding these treatments can be found in a prior
study [21]. Patients underwent two sets of CT scans
prior to treatment: a free-breathing three-dimensional
computed tomography (3D CT) scan for target defini-
tion and dose calculation and a four-dimensional CT
(4DCT) scan to assess respiratory motion. Two motion-
mitigation techniques were used during simulation and
treatment. In 7 patients, abdominal compression was
used during simulation and treatment to reduce the am-
plitude of motion. In the remaining 18 patients, respi-
ratory gating was used. Gross tumor volumes (GTV)
were drawn by the radiation oncologist on the planning
CT (as shown in red in Figure 1), and expanded to cre-
ate a Planning Target Volume (PTV). The GTV-to-PTV
expansion margins were typically 3-5 mm, and were de-
termined by the oncologist based on local anatomy. PTV
volumes were trimmed to avoid overlap with OARs. An
Internal Target Volume (ITV) was not used; however,
motion was taken into account in the design of the PTV.
For this, the PTV contour was overlaid on the 4DCT,
and compared against the observed range-of-motion of
the tumor boundaries. For patients managed with gat-
ing, the range-of-motion included only the 30% to 70%
phases of the 4DCT (end-exhale phases); whereas for pa-
tients managed with compression, this motion included
all phases. If needed, the PTV was expanded further to
encompass this range of motion. The EclipseTM Treat-
ment Planning System (Varian Medical Systems, Palo
Alto, CA) was used for planning and dose calculation.
Data from these clinical cases were analyzed under an
institutional review board (IRB) approved retrospective
research protocol.
Tumor trajectory
We utilized an existing pancreatic tumor motion
database measured in patients to quantify the effects of
motion on delivered dose. These tumor motion data were
collected in a previous study of SBRT for pancreatic can-
cer [22]. This motion library included 91 datasets of daily
pancreatic tumor motion derived from 19 patients. Raw
CBCT projection images were utilized to calculate tu-
mor motion data [23, 24, 25] with a previously developed
technique. A summary of the technique is given as fol-
lows:
1. In each projection image, the location of implanted
intratumoral fiducial markers was determined with
an automated template-matching algorithm? .
2. A 3D Gaussian probability model of the tumor tra-
jectory was formed with maximum-likelihood esti-
mation.
3. For each projection, the 3D position of the tumor
was estimated as the most likely position along
the line of detection according to the 3D Gaussian
model.
4. For each CBCT scan, a list of 892 tumor posi-
tions, which was also referred to as a tumor trajec-
tory, was output in patient geometry. The coordi-
nates of the tumor trajectories were in the anterior-
posterior (AP), left-right (LR) and superior-inferior
(SI) directions.
In each dataset, we calculated the time-resolved po-
sitions of the tumor throughout the CBCT, which were
composed of 892 samples of 3D positions over 1 minute.
Each sample was a 3D position estimated from one raw
CBCT projection image (892 projections per CBCT, each
acquired at 125 kVp, 1.5 mAs). These 19 patients were
not included in the 25 treatment plans we studied in this
paper.
Motion-convolved dose
One of the main effects of organ motion in IMRT is,
essentially, a blurring of the static dose distribution over
3the trajectory of the motion [26]. Methods based on con-
volution of the static dose distribution with a function
representing the distribution of uncertainties from intra-
treatment organ motion have been proposed before [27,
28, 29]. In this paper, 3D tumor trajectories were used as
the function representing internal organ motion. Motion-
convolved dose was calculated under two assumptions:
(1) the volume containing all structures of interest (the
tumor, the duodenum and the stomach) was a rigid vol-
ume and there was no rotation of the organs; and (2) the
static dose distribution was not affected by the internal
organ motion.
Dose volume histograms (DVHs) were calculated for
GTV, duodenum and stomach. Note that we utilized
coverage of the GTV (rather than the PTV) in our
motion-convolved dose calculation, where the GTV is
translated within the clinical dose distribution. This re-
flects the clinical scenario, where the tumor moves, and
the ITV/PTV expansion is intended to encompass tu-
mor motion and other uncertainties. The organ bound-
aries were generated from physician-drawn contours with
shape-based interpolation [30]. For each patient and each
tumor trajectory, the planned and motion-convolved dose
distributions and DVHs were calculated and evaluated
with several dose metrics.
Relevant dose metrics
To determine the allowable motion for each patient,
we computed the differences in dose metrics induced by
motion. To date, pancreatic SBRT has been largely im-
plemented at the single-institutional level, and as such
there is some heterogeneity in terms of dose constraints
and metrics reported in the literature [31, 32]. However,
there is general agreement that the main constraints in-
volve 1) coverage of the target volume and 2) maximum
point dose and/or high dose constraints to the stomach
and the duodenum. To understand the effects of motion
on pancreatic SBRT, a range of dose metrics were se-
lected to show the potential effects: (1) D98, which is the
dose covering 98% of the GTV; (2) D0.1cc d, which is the
maximum dose covering at least 0.1 cm3 of the duode-
num; (3) D0.1cc s, which is the maximum dose covering
at least 0.1 cm3 of the stomach; (4)V33 d, which is the
volume of the duodenum that receives more than 33 Gy;
and (5)V33 s, which is the volume of the stomach that
receives more than 33 Gy.
To get a broader understanding of the effect of mo-
tion on these plans, all 91-tumor trajectories were ap-
plied to each of the 25 treatment plans. In this analysis,
the differences between the static and motion-convolved
dose metrics (∆DMs, where each ∆DM = DMmotion −
DMstatic) were calculated. In this paper, we refer to
∆DMs as dosimetric errors. We divided the motion data
into four bins (based on the magnitude of motion in SI
direction) and calculated the mean and range of dosi-
metric errors for a group of patients. Prior work [22] has
shown that the mean [minimum—maximum] target ap-
parent motion ranges in SI direction for respiratory gat-
ing, abdominal compression and no motion mitigation
are 5.5 [1.5—8.4], 8.5 [1.6—17.1] and 13.9 [4.7—35.5], re-
spectively. The boundaries between the motion bins were
at 4, 7, and 10 mm, such that the mean apparent motion
ranges for respiratory gating, abdominal compression and
no motion mitigation are in the second, third and fourth
bins.
Personalized motion management requires knowledge
about the effects of motion for each individual. To re-
late motion with dosimetric endpoints, we modeled the
relation between ∆DMs and the magnitude of motion
in the SI direction for each patient. Based on the data
collected from the 25 patients, we deduced a model, ei-
ther linear or quadratic, for each dose metric. Data from
each patient were fitted by the models to derive a set of
patient-specific parameters. The models and the patient-
specific parameters were used to predict ∆DMs at any
motion magnitude. Details of this method are given in
the Supplemental Material.
Allowable motion for individual patient
To help guide clinical interpretation of our results, we
calculated limits for tumor motion based on a set of rep-
resentative dosimetric criteria. We first chose a set of
threshold values, which represented an excessive error in
the dose metrics. The thresholds we chose are 2 Gy for
∆D98, 5 Gy for ∆D0.1cc d and ∆D0.1cc s, 0.5 cm
3 for
∆V33 d and ∆V33 s. These thresholds were used to calcu-
late the upper limit on allowable motion (Lmax) for each
patient, which is the maximum magnitude of motion that
satisfies all the above five error thresholds. The motion
magnitude is represented by 95% confidence interval (CI)
in the SI direction.
We explored the effects of dose escalation, tumor vol-
ume and varying dosimetric-error thresholds on allowable
motion.
Dose escalation: To study the allowable motion when
the dose is escalated, we repeated the calculation for pre-
scription doses of 40 Gy and 50 Gy. We assumed the
planned dose distributions did not change and linearly
scaled the original dose distribution up to the given value.
To test the validity of this assumption, we re-planned 6
cases (the 3 most-sensitive and the 3 lease-sensitive to
motion) to 50 Gy and calculated allowable motion using
the re-planned dose distributions.
Tumor volume: To investigate if there is correlation
between the motion sensitivity of ∆DMs and tumor vol-
ume VGTV , we divided patients into two groups at the
median of the 25 tumor volumes, which is 20 cm3, and
quantified the effects of motion separately for these two
groups. These differences were assessed with an unpaired
t-test.
Sensitivity to dosimetric error thresholds: In order
to understand the effects of varying dosimetric-error
thresholds on allowable motion, we performed a sen-
sitivity analysis of the error thresholds on Lmax. We
4calculated Lmax under varying dosimetric error thresh-
olds. We fixed the thresholds for two dosimetric errors
at our initial choices, which are max(∆D98) = 2 Gy,
max(∆D0.1cc) = 5 Gy and max(∆V33) = 0.5 cm
3, and
varied the third threshold, multiplying the initial choice
by 0.5, 1 (no change) and 2.
RESULTS
Error in dose metrics (∆DMs): The absolute values
of the ∆DMs increase with the magnitude of tumor mo-
tion and are larger for larger tumors, as shown in Fig-
ure 2, where data from all 25 patients are presented as
box plots. The clinical dose distributions of patients with
tumors larger than 20 cm3 are affected more than those
from smaller tumors by tumor motion. The tumor vol-
ume affected ∆V33 d more severely than error in other
metrics considered in this paper. For reference, the av-
erage GTV volume was 20.0±10.7 cm3 (range 4.8—50.8)
and the average PTV volume was 41.8±18.5 cm3 (range
17.4—94.6).
The effects of motion on ∆DMs are highly variable be-
tween patients. Figure 3 shows how ∆DMs change as
functions of SI motion for 2 representative patients. For
each patient, the relations between ∆DMs and SI mo-
tion were fitted by a set of models. Each patient had
a set of fitting parameters. Details on the mathemati-
cal models and a quantitative measure of goodness of fit
are discussed in Supplement A. These personalized mod-
els, which relate dose metric errors to motion magnitude,
provide foundations to calculate allowable motion for in-
dividual patient.
In general, treatment plans broadly fall into two cat-
egories: those that are sensitive to tumor motion (eg.
patient #1 as shown in the left column of Figure 3) and
those that were relatively stable as the magnitude of tu-
mor motion increases (eg. patient #5 as shown in the
right column of Figure 3).
Allowable motion (Lmax): The allowable motion,
Lmax, of all 25 patients are combined into a boxplot in
Figure 4 (a). The relation between Lmax and the pre-
scription dose is presented for each patient in Figure 4
(b), where each color represents one patient. The same
boxplot as in Figure 4 (a) is drawn in the background
in Figure 4 (b) for reference. The plots show that (1)
different patients require different limits on target mo-
tion; (2) as prescription dose increases, allowable motion
decreases; (3) inter-personal variation is larger than the
variation caused by dose escalation.
The allowable motion for patients with tumors larger
than 20 cm3 and patients with tumors smaller than
20 cm3 are presented in Table I. As a side note, a VGTV of
20 cm3 on average corresponds to VPTV of 42 cm
3. The
mean [minimum—maximum] of VGTV for the two groups
of patients is 28.3 [20.1—50.8] and 12.3 [4.8—19.4] cm3.
Patients with larger tumors on average require a reduced
limit on target motion.
Figure 5 presents the mean and minimummaximum
ΔDMs vs. motion
Fig. 2 ∆DMs vs. motion for patients with small tumors (grey)
and large tumors (green). From top to bottom, ∆D98, ∆D0.1cc d,
∆V33 d, ∆D0.1cc s and ∆V33 s vs. motion are plotted. Lines indi-
cate mean; patches indicate 2.5th to 97.5th percentile. The data
are displayed for three dose levels. The patients were divided into
two groups based on tumor volumes, where the small tumor group
(VGTV < 20 cm
3) has 13 patients and the large tumor group
(VGTV ≥ 20 cm
3) has 12 patients.
range of the 25 Lmax for varying ∆D98 (left), ∆D0.1cc
(middle) and V33 (right). As stated previously, the error
threshold on one metric varies by multiplying the initial
choice by 0.5, 1 (no change), and 2; the error thresh-
olds on the remaining two metrics are fixed at our initial
choices, which are max(∆D98) = 2 Gy, max(∆D0.1cc) =
5 Gy and max(∆V33) = 0.5 cm3.
Sensitivity tests: Figure 5 presents the mean and
minimum—maximum range of the 25 Lmax for varying
∆D98 (left), ∆D0.1cc (middle) and V33 (right). As stated
previously, the error threshold on one metric varies by
multiplying the initial choice by 0.5, 1 (no change), and
2; the error thresholds on the remaining two metrics were
fixed at our initial choices, which are max(∆D98) = 2 Gy,
max(∆D0.1cc) = 5 Gy and max(∆V33) = 0.5 cm
3.
In our sensitivity test of tissue deformation, we calcu-
lated the difference in the deformation vector field from
5Table I Mean [minimum—maximum] allowable motion in mm and results of an unpaired two-sample student t-test to compare Lmax for
patients with tumor volume larger than 20 cm3 (12 patients) and smaller than 20 cm3 (13 patients).
(mm) 33 Gy 40 Gy 50 Gy
Lmax (all patients) 11.9 [6.3—22.4] 10.4 [5.2—19.1] 9.0 [4.2—16.0]
Lmax ( V > 20 cm3) 10.0 [6.3—16.2] 8.8 [5.2—15.0] 7.8 [4.2—13.9]
Lmax ( V < 20 cm3) 13.7 [6.8—22.4] 12.0 [6.2—19.1] 10.0 [5.6—16.0]
p-value 0.03 0.03 0.07
Fig. 3 ∆DMs vs. magnitude of motion for individual patients.
Data calculated from measured patient motion are plotted in black
dots. The fitted curves are plotted in red line.
the average deformation vector of the GTV. Differences
in the deformation vector field averaged less than 1 mm
at distances as high as 20 cm from the GTV. The stan-
dard deviation of the deformation differences were less
than 1 mm for duodenum, and less than 2 mm for the
stomach.
Dose scaling: For the 6 cases that we re-planned to
test our assumption of linear dose scaling, the mean
difference between allowable motion calculated from re-
planned dose distributions and from scaled dose distribu-
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Fig. 4 Allowable motion vs. prescription dose for all 25 patients (a)
and for each patient (b). (a): The boxplot shows the median (red
center line), [25th—75th] percentile (blue box) and [minimum—
maximum] range (black whiskers) of the 25 Lmax at each dose
level. (b): Each colored-solid line represents one patient; the same
boxplot in (a) is placed in the background for reference.
tions (Lmax scaleLmax replan) is 0.1 ± 0.3 mm, which on
a percentage basis equates to 1.3± 5.7%.
DISCUSSION
As more institutions explore dose escalation in pancre-
atic SBRT, it is necessary to understand the potential
risks and benefits. Motion is a first-order driver of un-
certainty in abdominal SBRT, and the erratic nature of
pancreatic motion [33, 34] makes accounting for this un-
certainty difficult. A widely available technique to assess
respiratory motion of pancreatic tumors is 4DCT; how-
ever, numerous studies have demonstrated that 4DCT
underestimates the actual range of motion for pancreatic
tumors [35, 36]. In this study, we developed a method
to quantify the sensitivity of a given plan to motion,
and tested this method using realistic tumor motion data
measured in patients to quantify the effects of motion on
our clinical dose distributions. By relating realistic mo-
tion data to dosimetric endpoints, we were able to estab-
lish limits on the amount of motion that can be allowed in
this cohort without exceeding error thresholds. We found
that the amount of allowable motion decreased as dose
was escalated; however, this effect was small compared
to inter-patients variations. We also found an inverse re-
lationship between target volume and allowable motion.
This makes intuitive sense, as in general, the boundaries
of larger tumors are closer to the boundaries of OARs,
and larger tumor volumes require more integral dose to
provide adequate tumor coverage. The inverse relation-
ship implies that the limits on motion should be tightened
for large tumors (or relaxed for smaller tumors).
6Fig. 5 Upper limit on allowable motion (Lmax) vs. varying error thresholds on ∆D98 (left), ∆D0.1cc (middle) and ∆V33 (right). Each
dosimetric-error threshold is varied at three values with the other two error thresholds fixed. When an error threshold is not varied, the
value is fixed at: ∆D98 = 2 Gy, ∆D0.1cc = 5 Gy, and ∆V33 = 0.5 cm3. Lines indicate mean of Lmax; bars indicate range.
In our dataset, a conservative limit of 6.3 mm motion
ensured safe treatment of all patients at current dose
levels. This value is highly dependent on the process
through which the target volume was constructed, and
the motion margins that were applied. While this spe-
cific result may apply only to our patient cohort, several
results can be applied more broadly. First, we found
considerable differences between patients (exceeding the
differences due to dose escalation). This suggests that
patient-specific dose escalation may be feasible, and that
some patients could safely receive treatments that are
more aggressive. Secondly, we have developed a method
that would allow the determination of allowable motion
prior to treatment. Taken together, one could envision a
clinical scenario where, at the time of simulation, the pa-
tient undergoes comprehensive motion evaluation (using
either fluoroscopy or CBCT in conjunction with a com-
putational technique to extract motion data) [37, 24, 38].
Using the methods presented in this work, these motion
data could then be used to evaluate the sensitivity of a
given plan to motion, and an appropriate motion mitiga-
tion strategy could be implemented. In rare cases (with
little predicted toxicity), it may even be possible to sim-
ply expand treatment margins to ensure coverage. On
the other hand, in challenging dose-escalated scenarios,
it may be appropriate to implement real-time imaging
methods to increase the accuracy of treatment to better
than 5 mm [39].
Since unmitigated pancreatic motion is generally larger
than 6.3 mm, our data imply that some form of motion
mitigation is necessary. Minn et. al. [40] found that the
range-of-motion in the SI direction can vary from 4.5 to
48.8 mm (mean 20.8 mm), and Feng et. al. [33] found a
mean range-of-motion of 20± 10 mm. Clinically, motion
management techniques, such as abdominal compression,
respiratory gating, and real-time tumor-tracking [20], can
be applied. In a prior study comparing gating and com-
pression for pancreatic SBRT [22], it was found that ab-
dominal compression resulted in an average of 8.5 mm
of motion in the SI direction (range 2—17 mm), whereas
the average apparent range of tumor motion during res-
piratory gating was 5.5 mm (range 2—8 mm). Taken
together, these results suggest that respiratory gating
may be the best one-size-fits-all approach for pancreatic
SBRT. However, we also found significant differences be-
tween patients, and our data suggests that many patients
could be treated safely under more relaxed conditions.
There are several important limitations to our work
that must be considered. Our dose model assumes rigid
motion within the abdomen, whereas previous work indi-
cates that the pancreas can undergo deformation during
respiration [33]. However, the deformation observed was
up to 5 mm with a mean of 1—2 mm [33], which is small
compared to the typical magnitude of pancreatic motion
(1—2 cm). Furthermore, another study [41] compared
rigid and deformable dose accumulation in liver SBRT
and found that rigid dose accumulation led to dose er-
rors averaging less than 1% of prescription dose for tumor
and normal tissue (ranging from -5.1%—8.3%). In our
sensitivity analysis, this assumption of rigid motion re-
sulted in average errors less than 1 mm. Given these
data, we argue that errors due to rigid assumptions are
small compared to dosimetric changes caused by motion.
However, future work on this topic should include the ef-
fects of deformation (perhaps using intrafraction images
obtained from MR linacs). It is also important to un-
derstand the effects of inter-fraction anatomical changes.
Day-to-day changes in patient anatomy (such as stom-
ach/bowel gas) can cause dosimetric changes, and studies
have found that adaptive re-planning in pancreatic SBRT
can result in dosimetric benefits [42, 43]. The optimal
approach may involve a combination of patient-specific
motion management and adaptive replanning. As more
institutions explore dose-escalated therapies, it is impera-
tive to understand the benefits and risks of different tech-
niques, and to choose the most appropriate approach.
Another limitation is the ambiguity about which dose
metrics are most relevant to pancreatic SBRT. Studies
have shown that pancreatic SBRT toxicity is correlated
with maximum dose received by an OAR (Dmax), which
refers to maximum dose to 1 cm3 in one study [31] and
maximum dose to 0.035 cm3 in another [32]. We chose to
use D0.1cc to represent Dmax. Murphy et al. [31] has also
shown that duodenum toxicity is correlated with the vol-
7ume of duodenum receiving significant dose. Therefore,
we chose to use V33 to represent volume effect. The last
metric we chose, which is D98 of the GTV, represents
tumor coverage. We anticipate that future clinical tri-
als will provide more exact answers regarding pancreatic
SBRT dose metrics; however, we chose a representative
set of metrics that can be broadly applied to understand
the relationship between motion, local control, and toxi-
city. There is also ambiguity about how much change in
dose metrics is clinically relevant. We performed a sensi-
tivity analysis (Figure 5) to understand the impact of our
choice of thresholds, but found that differences between
patients (∼1 cm) were much greater than differences due
to choice of thresholds (2—3 mm). Once again, future
clinical trials will provide better information in this re-
gard, but our method provides a framework for relating
these values to motion.
It should be noted that, in this work, we simulated dose
escalation by linearly scaling 33 Gy dose distributions to
40 or 50 Gy. This is somewhat unrealistic, as a clinical
dose-escalated plan would be more optimized to spare
normal tissue from harm. Better plan optimization would
likely result in slightly more allowable motion. However,
our data have shown a conservative limit of 4.2 mm of
motion under linear-scaling to 50 Gy; and based on 6 re-
planned cases, the difference in maximum allowable mo-
tion is 0.1 ± 0.3 mm under clinical dose escalation. The
error introduced by the unrealistic dose-scaling is small
compared to the difference between patients. Therefore,
it is reasonable to claim that the differences in allow-
able motion between individual patients are much larger
than the changes caused by dose escalation, as demon-
strated by Figure 4. Implementing a patient-specific mo-
tion mitigation approach requires knowing what makes
a given plan more sensitive to motion. In this study, we
found that allowable motion was significantly smaller in
patients with larger tumors. Other features of the pa-
tients, such as the distance from the tumor to an OAR,
may correlate with individual allowable motion as well.
We investigated other potential factors (such as minimum
distance from the tumor to duodenum or stomach), but
were unable to find a clinically relevant way to predict
the sensitivity of a given plan to motion. Future work
will incorporate additional patient data, and attempt to
develop metrics of motion sensitivity. There is potential
for these sorts of metrics to be included in radiotherapy
plan optimization, leading to the creation of plans that
are more robust against tumor motion.
CONCLUSIONS
In a cohort of pancreatic cancer patients treated at our
institution with 33 Gy/5 fractions, a conservative limit
of 6.3 mm of motion prevents significant deviations in
target coverage and OAR sparing from the radiotherapy
plan. We observed tighter limits on allowable motion in
patients with larger tumors, and for dose-escalated treat-
ment plans. However, the largest variations in the effects
of motion on ∆DMs stem from differences between pa-
tients. Dose escalation can potentially be carried out for
a sub-population of patients without additional clinical
burden. We present a method to recognize this group
of patients and provide guidance on personalized motion
management.
CONFLICT OF INTEREST
The University of Colorado School of Medicine and
authors Campbell, Jones, and Miften have filed a provi-
sional patent application for the fiducial marker tracking
technique used in this work.
ACKNOWLEDGMENT
This work was funded in part by the National Insti-
tute of Health under award number K12CA086913, the
University of Colorado Cancer Center/ACS IRG #57-
001-53 from the American Cancer Society, the Boettcher
Foundation, and Varian Medical Systems. These fund-
ing sources had no involvement in the study design; in
the collection, analysis, and interpretation of data; in the
writing of the manuscript; or in the decision to submit
the manuscript for publication.
REFERENCES
[1] Hidalgo M. Pancreatic cancer. NEJM
2010;362(17):160517.
[2] Chuong MD, Springett GM, Freilich JM, Park CK, Weber
JM, Mellon EA, et al. Stereotactic body radiation therapy for
locally advanced and borderline resectable pancreatic cancer
is effective and well tolerated. IJROBP 2013;86(3):51622.
[3] Koong AC, Christofferson E, Le QT, Goodman KA, Ho A,
Kuo T, et al. Phase II study to assess the efficacy of conven-
tionally fractionated radiotherapy followed by a stereotactic
radiosurgery boost in patients with locally advanced pancre-
atic cancer. IJROBP 2005;63(2):3203.
[4] Koong AC, Le QT, Ho A, Fong B, Fisher G, Cho C,
et al. Phase I study of stereotactic radiosurgery in pa-
tients with locally advanced pancreatic cancer. IJROBP
2004;58(4):101721.
[5] Rosati LM, Kumar R, Herman JM. Integration of stereo-
tactic body radiation therapy into the multidisciplinary man-
agement of pancreatic cancer. Seminars in Radiation Oncol-
ogy 2017;27(3):256 67.
[6] Herman JM, Chang DT, Goodman KA, Dholakia AS, Ra-
man SP, HackerPrietz A, et al. Phase 2 multi-institutional
trial evaluating gemcitabine and stereotactic body radiother-
apy for patients with locally advanced unresectable pancreatic
adenocarcinoma. Cancer 2015;121(7):112837.
[7] Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock
A, Buchbinder E, et al. Induction gemcitabine and stereo-
tactic body radiotherapy for locally advanced nonmetastatic
pancreas cancer. IJROBP 2011;81(4):e61522.
[8] Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA,
Fisher GA, et al. Stereotactic radiotherapy for unresectable
adenocarcinoma of the pancreas. Cancer 2009;115(3):66572.
8[9] Ceha HM, van Tienhoven G, Gouma DJ, Veenhof CH,
Schneider CJ, Rauws EA, et al. Feasibility and efficacy of
high dose conformal radiotherapy for patients with locally
advanced pancreatic carcinoma. Cancer 2000;89(11):22229.
[10] Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R,
Pauken KE, Stelekati E, et al. Radiation and dual check-
point blockade activates nonredundant immune mechanisms
in cancer. Nature 2015;520(7547):373.
[11] Golden EB, Chhabra A, Chachoua A, Adams S,
Donach M, FentonKerimian M, et al. Local radiother-
apy and granulocyte-macrophage colony-stimulating factor
to generate abscopal responses in patients with metastatic
solid tumours: a proof-of-principle trial. Lancet Oncology
2015;16(7):795803.
[12] Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng
Y, et al. Therapeutic effects of ablative radiation on local
tumor require CD8+ T cells: changing strategies for cancer
treatment. Blood 2009;114(3):58995.
[13] Brown JM, Brenner DJ, Carlson DJ. Dose escalation,
not new biology, can account for the efficacy of SBRT with
NSCLC. IJROBP 2013;85(5):1159.
[14] Golden DW, Novak CJ, Minsky BD, Liauw SL. Radia-
tion dose ≥54 Gy and CA 199 response are associated with
improved survival for unresectable, non-metastatic pancre-
atic cancer treated with chemoradiation. Radiation Oncology
2012;7(1):156.
[15] Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW.
Radiation-induced vascular damage in tumors: implications
of vascular damage in ablative hypofractionated radiotherapy
(SBRT and SRS). Radiation research 2012;177(3):31127.
[16] Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R,
Flaig T, Lewis K, et al. Stereotactic body radiation ther-
apy for melanoma and renal cell carcinoma: impact of single
fraction equivalent dose on local control. Radiation Oncology
2011;6(1):34.
[17] Timmerman R, Paulus R, Galvin J, Michalski J,
Straube W, Bradley J, et al. Stereotactic body radia-
tion therapy for inoperable early stage lung cancer. JAMA
2010;303(11):10706.
[18] Available online at www.clinicaltrials.gov [Acccessed:
10/20/2017]; 2017. Searching terms: SBRT AND dose es-
calation AND pancreatic cancer.
[19] Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L,
Pedersen J, et al. Phase-II study on stereotactic radiotherapy
of locally advanced pancreatic carcinoma. Radiotherapy and
oncology 2005;76(1):4853.
[20] Keall PJ, Mageras GS, Balter JM, Emery RS, Forster
KM, Jiang SB, et al. The management of respiratory mo-
tion in radiation oncology report of AAPM Task Group 76.
Medical physics 2006;33(10):3874900.
[21] Vinogradskiy Y, Goodman KA, Schefter T, Miften M,
Jones BL. The clinical and dosimetric impact of real-time tar-
get tracking in pancreatic SBRT. IJROBP, 2019;103(1):268-
275.
[22] Campbell WG, Jones BL, Schefter T, Goodman
KA, Miften M. An evaluation of motion mitigation tech-
niques for pancreatic SBRT. Radiotherapy and Oncology
2017;124(1):168-173.
[23] Campbell WG, Miften M, Jones BL. Automated tar-
get tracking in kilovoltage images using dynamic templates
of fiducial marker clusters. Medical physics 2017;44(2):36474.
[24] Jones BL, Westerly D, Miften M. Calculating tumor tra-
jectory and dose-of-the-day using cone-beam CT projections.
Medical physics 2015;42(2):694 702.
[25] Poulsen PR, Cho B, Keall PJ. A method to estimate mean
position, motion magnitude, motion correlation, and trajec-
tory of a tumor from cone-beam CT projections for image-
guided radiotherapy. IJROBP 2008;72(5):158796.
[26] Bortfeld T, Jokivarsi K, Goitein M, Kung J, Jiang SB.
Effects of intrafraction motion on IMRT dose delivery: sta-
tistical analysis and simulation. PMB 2002;47(13):2203.
[27] Lujan AE, Larsen EW, Balter JM, Ten Haken RK. A
method for incorporating organ motion due to breathing into
3D dose calculations. Medical physics 1999;26(5):71520.
[28] McCarter S, Beckham W. Evaluation of the validity of a
convolution method for incorporating tumour movement and
set-up variations into the radiotherapy treatment planning
system. PMB 2000;45(4):923.
[29] Lens E, Kotte AN, Patel A, Heerkens HD, Bal M, van
Tienhoven G, et al. Probabilistic treatment planning for pan-
creatic cancer treatment: prospective incorporation of respi-
ratory motion shows only limited dosimetric benefit. Acta
Oncologica 2017;56(3):398404.
[30] Herman GT, Zheng J, Bucholtz CA. Shape-based in-
terpolation. IEEE Computer Graphics and Applications
1992;12(3):6979.
[31] Murphy JD, Christman-Skieller C, Kim J, Dieterich S,
Chang DT, Koong AC. A dosimetric model of duodenal toxic-
ity after stereotactic body radiotherapy for pancreatic cancer.
IJROBP 2010;78(5):14206.
[32] Goldsmith C, Price P, Cross T, Loughlin S, Cowley I,
Plowman N. Dose-volume histogram analysis of stereotactic
body radiotherapy treatment of pancreatic cancer: A focus
on duodenal dose constraints. In: Seminars in radiation on-
cology; vol. 26. Elsevier; 2016, p. 14956.
[33] Feng M, Balter JM, Normolle D, Adusumilli S, Cao Y,
Chenevert TL, et al. Characterization of pancreatic tumor
motion using cine MRI: surrogates for tumor position should
be used with caution. IJROBP 2009;74(3):88491.
[34] Heerkens HD, van Vulpen M, van den Berg CA, Ti-
jssen RH, Crijns SP, Molenaar IQ, et al. MRI-based tu-
mor motion characterization and gating schemes for radiation
therapy of pancreatic cancer. Radiotherapy and Oncology
2014;111(2):252 7.
[35] Lens E, van der Horst A, Kroon PS, van Hooft JE,
Dvila Fajardo R, Fockens P, van Tienhoven G, Bel A. Dif-
ferences in respiratory-induced pancreatic tumor motion be-
tween 4D treatment planning CT and daily cone beam CT,
measured using intratumoral fiducials. Acta Oncologica.
2014;53(9):1257-64.
[36] Rankine LJ, Wan H, Parikh PJ, Maughan NM, Poulsen
PR, Santanam L. Cone Beam CT Measures Abdominal Tu-
mor Motion Better Than 4DCT and Equal to On-table Flu-
oroscopy. IJROBP. 2015;93(3):S116.
[37] Poulsen PR, Cho B, Keall PJ. Real-time prostate trajec-
tory estimation with a single imager in arc radiotherapy: a
simulation study.PMB 2009;54(13):4019.
[38] Berbeco RI, Nishioka S, Shirato H, Chen GT, Jiang SB.
Residual motion of lung tumours in gated radiotherapy with
external respiratory surrogates. PMB 2005;50(16):3655.
[39] Keall PJ, Nguyen DT, OBrien R, Caillet V, Hewson E,
Poulsen PR, et al. The first clinical implementation of real-
time image-guided adaptive radiotherapy using a standard
linear accelerator. Radiotherapy and Oncology 2018;127(1):6-
11.
9[40] Minn AY, Schellenberg D, Maxim P, Suh Y, McKenna
S, Cox B, et al. Pancreatic tumor motion on a single plan-
ning 4D-CT does not correlate with intrafraction tumor mo-
tion during treatment. American journal of clinical oncology
2009;32(4):3648.
[41] Velec M, Moseley JL, Eccles CL, Craig T, Sharpe MB,
Dawson LA, et al. Effect of breathing motion on radiotherapy
dose accumulation in the abdomen using deformable registra-
tion. IJROBP 2011;80(1):26572.
[42] Bohoudi O, Bruynzeel A, Senan S, Cuijpers J, Slotman B,
Lagerwaard F, et al. Fast and robust online adaptive plan-
ning in stereotactic MR-guided adaptive radiation therapy
(SMART) for pancreatic cancer. Radiotherapy and Oncology
2017;125(3):43944.
[43] Li Y, Hoisak JD, Li N, Jiang C, Tian Z, Gautier Q, et
al. Dosimetric benefit of adaptive re-planning in pancreatic
cancer stereotactic body radiotherapy. Medical Dosimetry
2015;40(4):31824.
SUPPLEMENT A
The mathematical models are chosen based on two
merits: (1) ability to account for the trend of the data,
and (2) simplicity. We chose either linear or quadratic
models that only require maximum of two fitting param-
eters. We present the models and the goodness-of-fit
statistics.
.A. ∆D98
We used a piecewise-parabola function to describe the
trend of ∆D98 with changing motion magnitude. The
piecewise parabola function was given by
∆D98(x) =
{
0 , if x < p2 ;
p1 · (x − p2)
2 , if x ≥ p2 ;
(1)
where x is the 95% confidence interval (CI) of motion
range in superior-inferior (SI) direction, p1 and p2 are
two fitting parameters.
.B. ∆D0.01cc
We used a piecewise linear function to describe the
trend of ∆D0.01cc. The piecewise linear function was
given by
∆D0.01cc(x) =
{
0 , if x < p2 ;
p1 · (x − p2) , if x ≥ p2 ;
(2)
where x is the 95% CI of motion range in SI direction,
p1 and p2 are two fitting parameters. This model is used
for ∆D0.01cc in both duodenum and stomach.
.C. ∆V33
The trend of ∆V33 was described by a parabola func-
tion of form
∆V33(x) = p1 · x
2, (3)
where x is the 95% CI of motion range in SI direction,
p1 is the only fitting parameter. This model is used for
∆V33 in both duodenum and stomach.
.D. Goodness-of-fit statistics
After fitting data with our models, we first visually in-
spected the goodness of fit. As shown in example plots of
two patients, the models fitted the trend of the data qual-
itatively. To evaluate the goodness of fit quantitatively,
we calculated the root mean squared error (RMSE). For
each metric, we calculated the mean and standard devi-
ation of the RMSE over 25 patients and the results are
presented in Table II. The RMSE values were small com-
pared to the range of the ∆DMs, which indicates that
the models were useful for prediction.
Table II The mean and standard deviation of RMSE over 25 pa-
tients.
Rx dose (Gy) 33 40 50
∆D98 (Gy) 0.3±0.2 0.4±0.3 0.5±0.3
∆D0.1cc D (Gy) 0.7±0.2 0.9±0.3 1.1±0.3
∆V33 D (cm
3) 0.0±0.0 0.1±0.0 0.1±0.1
∆D0.1cc S (Gy) 0.4±0.3 0.5±0.3 0.6±0.4
∆V33 S (cm
3) 0.0±0.0 0.0±0.0 0.0±0.0
